

meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 6, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04-8189 Filed 4-9-04; 8:45 am]

BILLING CODE 4163-19-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Drug Safety and Risk Management Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Drug Safety and Risk Management Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on May 5, 2004, from 8 a.m. to 5 p.m.

*Location:* Center for Drug Evaluation and Research Advisory Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville MD.

*Contact Person:* Shalini Jain, Center for Drug Evaluation and Research (HFD-21), 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, e-mail: [jains@cder.fda.gov](mailto:jains@cder.fda.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512535. Please call the Information Line for up-to-date information on this meeting. Background materials for this meeting when available will be posted on the Internet 1 business day before the meeting at [www.fda.gov/ohrms/dockets/ac/acmenu.htm](http://www.fda.gov/ohrms/dockets/ac/acmenu.htm).

*Agenda:* From 8 a.m. to 3 p.m., the committee will discuss medication errors relating to the labeling and packaging of various drug products in

low-density polyethylene plastic vials. From 3 p.m. to 5 p.m., the committee will receive a progress report on the new drug application (NDA) 21-107, LOTRONEX (alosetron hydrochloride), GlaxoSmithKline, Risk Management Program.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 27, 2004. Oral presentations from the public will be scheduled between approximately 11 a.m. and 11:30 a.m. and between approximately 3 p.m. and 3:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 27, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Shalini Jain at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 5, 2004.

**Peter J. Pitts,**

*Associate Commissioner for External Relations.*

[FR Doc. 04-8126 Filed 4-9-04; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with Section 3506(c)(2)(A) of the Paperwork

Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (301) 443-7978.

Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

*Proposed Project:* 2005 National Survey on Drug Use and Health—(OMB No. 0930-0110, Revision)—The National Survey on Drug Use and Health (NSDUH), formerly the National Household Survey on Drug Abuse (NHSDA), is a survey of the civilian, noninstitutionalized population of the United States 12 years old and older. The data are used to determine the prevalence of use of tobacco products, alcohol, illicit substances, and illicit use of prescription drugs. The results are used by SAMHSA, ONDCP, Federal government agencies, and other organizations and researchers to establish policy, direct program activities, and better allocate resources.

For the 2005 NSDUH, additional questions are being planned regarding internet use and access. Questions on neighborhood cohesiveness are slated to be removed, and income questions are scheduled to be re-designed. The remaining modular components of the questionnaire will remain essentially unchanged except for minor modifications to wording.

As with all NSDUH/NHSDA surveys conducted since 1999, the sample size of the survey for 2005 will be sufficient to permit prevalence estimates for each of the fifty states and the District of Columbia. The total annual burden estimate is shown below:

|                              | Number of responses | Responses/ respondent | Average burden/ response (hr.) | Total burden (hrs) |
|------------------------------|---------------------|-----------------------|--------------------------------|--------------------|
| Household Screening .....    | 182,250             | 1                     | .083                           | 15,127             |
| Interview .....              | 67,500              | 1                     | 1.0                            | 67,500             |
| Screening Verification ..... | 5,559               | 1                     | 0.067                          | 372                |
| Interview Verification ..... | 10,125              | 1                     | 0.067                          | 678                |
| Total .....                  | 182,259             | .....                 | .....                          | 83,677             |

Send comments to Nancy Pearce, SAMHSA Reports Clearance Officer, Room 16-105, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received by June 11, 2004.

Dated: April 5, 2004.

**Anna Marsh,**

*Executive Officer, SAMHSA.*

[FR Doc. 04-8188 Filed 4-9-04; 8:45 am]

BILLING CODE 4162-20-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Notice of Request for Applications for Grant Program To Provide Substance Abuse Treatment and Reentry Services to Sentenced Juveniles and Young Adult Offenders Returning to the Community From the Correctional System (Short Title: Young Offender Reentry Program) (TI 04-002)

**Authority:** Section 509 of the Public Health Service Act, as amended and subject to the availability of funds.

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice of request for applications for Grant Program to Provide Substance Abuse Treatment and Reentry Services to Sentenced Juveniles and Young Adult Offenders Returning to the Community from the Correctional System (Short Title: Young Offender Reentry Program) (TI 04-002).

**SUMMARY:** The United States Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Treatment (CSAT) is accepting applications for fiscal year (FY) 2004 grants to expand and/or enhance substance abuse treatment and related reentry services in agencies currently providing supervision of and services to *sentenced* juvenile and young adult offenders returning to the community from *incarceration* for criminal/juvenile offenses. Applicants are expected to

form stakeholder partnerships that will plan, develop and provide community-based substance abuse treatment and related reentry services for the targeted populations. Because reentry transition must begin in the correctional or juvenile facility before release, funding may be used for limited activities in institutional correctional settings in addition to the expected community-based services.

**DATES:** Applications are due on June 15, 2004.

**FOR FURTHER INFORMATION CONTACT:** For questions on program issues, contact: Kenneth W. Robertson, Team Leader, Systems Improvement Branch, Division of Services Improvement, SAMHSA/CSAT, 5600 Fishers Lane, Rockwall II, Suite 740, Rockville, MD 20857, Phone: (301) 443-7612, Fax: (301) 443-8345, E-mail: [kroberts@samhsa.gov](mailto:kroberts@samhsa.gov).

For questions on grants management issues, contact: Kathleen Sample, Division of Grants Management, Substance Abuse and Mental Health Services Administration/OPS, 5600 Fishers Lane, Rockwall II 6th Floor, Rockville, MD 20857, Phone: (301) 443-9667, Fax: (301) 443-6468, E-mail: [ksample@samhsa.gov](mailto:ksample@samhsa.gov).

**SUPPLEMENTARY INFORMATION:**  
*Catalogue of Federal Domestic Assistance (CFDA) No.: 93.243.*

#### Key Dates

**Application Deadline:** June 15, 2004  
**Intergovernmental Review (E.O. 12372):** Letters from State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.

**Public Health System Impact Statement (PHSIS)/Single State Agency Coordination:** Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.

**Date of Issuance:** April 2004.

#### Table of Contents

- I. Funding Opportunity Description
  1. Introduction
  2. Expectations
- II. Award Information
  1. Award Amount
  2. Funding Mechanism

#### III. Eligibility Information

1. Eligible Applicants
2. Cost Sharing or Matching
3. Other

#### IV. Application and Submission Information

1. Address To Request Application Package
2. Content and Form of Application Submission
3. Submission Dates and Times
4. Intergovernmental Review (E.O. 12372) Requirements
5. Funding Limitations/Restrictions
6. Other Submission Requirements

#### V. Application Review Information

1. Evaluation Criteria
  2. Review and Selection Process
- #### VI. Award Administration Information
1. Award Notices
  2. Administrative and National Policy Requirements
  3. Reporting

#### VII. Agency Contacts

- Appendix A—Checklist for Formatting Requirements and Screenout Criteria for SAMHSA Grant Applications
- Appendix B—Glossary
- Appendix C—Statement of Assurance

### I. Funding Opportunity Description

#### 1. Introduction

As authorized under section 509 of the Public Health Service Act, the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), announces the availability of Fiscal Year 2004 grants to expand and/or enhance substance abuse treatment and related reentry services in agencies currently providing supervision of and services to *sentenced* juvenile and young adult offenders returning to the community from *incarceration* for criminal/juvenile offenses. Applicants are expected to form stakeholder partnerships that will plan, develop and provide community-based substance abuse treatment and related reentry services for the targeted populations. Because reentry transition must begin in the correctional or juvenile facility before release, funding may be used for limited activities in institutional correctional settings in addition to the expected community-based services. (**NOTE:** see **EXPECTATIONS** section below for allowable services in incarcerated settings.)